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but can also mobilize many different antibacterial defenses. This study tested the hypothesis whereby 23 stimulation of the innate immune receptor Toll-like receptor 4 (TLR4) can be combined with antibiotics in the 24 treatment of invasive pneumonia. In a mouse model of Streptococcus pneumoniae infection, a single oral 25 administration of low-dose amoxicillin (AMX) or the systemic delivery of monophosphoryl lipid A (MPLA, a 26 clinically-approved TLR4 activator) decreased the bacterial load in lung and spleen, although this was not 27 sufficient for long-term survival. In contrast, a single treatment with a combination of MPLA and AMX induced 28 significant bacterial clearance with little to no regrowth over time, and was associated with longer survival. 29
Upregulation of genes related to granulocyte infiltration in lung tissue and elevation of blood levels of pro-30 inflammatory cytokines was immediate and transient in MPLA-treated mice; this indicates activation of the 31 innate immune system in a context of infection. Combination treatment was associated with a well-preserved 32 lung tissue architecture and more rapid recovery from inflammation -suggesting that immune activation by 33 MPLA does not exacerbate pneumonia-induced damage. After AMX administration, plasma AMX 34 concentrations rapidly reached the maximum and declined, whereas the downstream effects of MPLA extended 35 beyond AMX elimination; these findings suggested a two-step effect. Our results demonstrated that leveraging 36 host innate immunity increases the efficacy of antibiotic therapy in bacterial pneumonia. 37
38

INTRODUCTION 39
The discovery and development of antibiotics in the 20 th century was a major turning point in medicine; 40 it enabled the successful treatment and/or prevention of many infectious diseases in humans and in other 41 animals. Decades later, these drugs are back in the headlines but for the wrong reasons: the alarming decline in 42 their therapeutic effectiveness and the spread in antimicrobial resistance (AMR). The latter is a major threat to 43 human health because it compromises our ability to treat bacterial infections and to carry out medical procedures 44 that rely on prophylactic antibiotic use, such as chemotherapy, transplantation, and surgery (1). A single 45 pathogen can express multiple resistance mechanisms, which in turn can often confer protection against several 46 classes of antibiotics. In a clinical setting, this usually necessitates treatment with a "last resort" antibiotic or 47 with combinations of antibiotics. In 2015, a report from the World Health Organization raised concerns about 48 the lack of new antibiotics in development (2). This emphasizes the need to come up with innovative anti-49 infective approaches for treating resistant pathogens and preventing the further dissemination of AMR. 50
Advances in medicine and technology have provided deeper insights into immunology and thus 51 increased the viability of host-directed therapeutic strategies. For example, the targeted stimulation of innate 52 immunity using immunomodulatory drugs has gained much attention in recent years (3). This approach has 53 three main advantages: (i) it makes use of universal, built-in machinery that is ready to activate in most 54 individuals, (ii) it has both anti-infective and pro-recovery effects, and (iii) the complex innate immune system 55 mobilizes many different effectors through a tightly coordinated string of events, and thus counters the potential 56 development of AMR by invading pathogens. The host's recognition of immediate danger is instrumental in 57 mounting a successful defense against invading pathogens. In vivo, many cell types are equipped with pattern-58 4 therapies against viral and bacterial infections (3, 5). Monophosphoryl lipid A (MPLA) is a derivative of the 66 immunostimulatory lipid A component of the outer-membrane-expressed lipopolysaccharide (LPS) from the 67 bacterium Salmonella minnesota R595 (6). Lipopolysaccharide itself is highly toxic, due to its ability to strongly 68 activate TLR4 downstream signaling at low doses via both of the receptor's adaptor proteins, namely myeloid 69 differentiation primary response 88 (MyD88) and Toll/interleukin-1 receptor domain-c activation protein 70 inducing interferon beta (TRIF). In contrast, activation of TLR4 by MPLA is biased towards TRIF-dependent 71 TLR4 signaling, making MPLA safe for use in humans (7). Monophosphoryl lipid A induces a significant but 72 attenuated innate immune response (8-10); this property is related to the differences in its molecular structure 73 vs. LPS (11, 12) . The combination of immunostimulatory activity and low toxicity make MPLA an attractive 74 candidate for therapeutic use in humans. Years of research have paved the way to MPLA becoming the first 75 TLR agonist to be licensed as an adjuvant in certain vaccine formulations (12-14). Despite the growing body 76 of literature data (indicating continued interest in finding further applications for MPLA), most studies have 77 focused on its use as a prophylactic treatment. Indeed, MPLA has been shown to confer protection against 78 infections by (i) Pseudomonas aeruginosa in burn-wounds, (ii) Staphylococcus aureus under post-hemorrhagic 79 conditions, and (iii) nontypeable Haemophilus influenzae in the nasopharynx (15-18). In view of these 80 observations, we hypothesized that MPLA may be a viable treatment against an ongoing bacterial infection, 81 and so looked into both its applicability and efficacy as an anti-infective therapy. To the best of our knowledge, 82 the only other previous study of this approach was performed in the context of fungal infection (19) . 83
In order to tackle the challenges of developing alternative therapeutic strategies against bacterial 84 infections and combating the spread of AMR, we designed and performed the present proof-of-concept study. 85
The prime objective was to establish whether host immune responses can be leveraged to achieve a successful 86 treatment outcome. Using a previously established murine model of invasive pneumococcal disease (20, 21), 87
we determined whether deliberately TLR4-activated innate immune responses can constitute an adjunct to 88 standard antibiotic therapy, improve the latter's efficacy, and/or promote quicker tissue recovery after an 89 infection. To this purpose, the study investigates the MPLA effect on amoxicillin (AMX), a beta-lactam 90 antibiotic used as first-line treatment against S. pneumoniae. 91
RESULTS 92
The combination of MPLA and amoxicillin increases S. pneumoniae clearance and extends survival 93
Intraperitoneal administration of MPLA to naïve animals (0.5 to 50 µg per mouse) increased the mRNA and 94 protein levels of inflammatory mediators -indicating MPLA's ability to induce innate immune responses three 95 hours post-administration ( Figure S1) . The magnitude of the systemic immune responses (i.e. in the liver and 96 blood) was strongly dependent on the dose of MPLA. Innate immune responses were also observed in the lungs 97 after the systemic injection of MPLA, albeit only at the highest dose (50 µg). This result suggests that the 98 systemic administration of MPLA promotes both systemic and pulmonary immune responses -a feature that 99 could potentially be exploited in the host-directed therapy of respiratory infectious diseases. 100
We next looked at whether MPLA's immunomodulatory effects impacted the bacterial load during 101 pneumococcal infection in mice when the TLR4 activator was administered together with AMX, a first-line 102 treatment against S. pneumoniae. Twelve hours after intranasal inoculation with S. pneumoniae, Swiss (CD-1) 103 mice received either a sub-curative dose of AMX (10 µg per animal; 0.4 mg/kg, administered by oral gavage), 104 MPLA (50 µg per animal; 2.0 mg/kg, administered by intraperitoneal injection) or a combination of the two 105 treatments (AMX+MPLA). Bacterial counts in the lungs and spleen were determined at different time points as 106 surrogate markers of pneumonia and bacterial dissemination, respectively (Figure 1) . At 24 hours post-107 infection, the bacterial loads in the lungs and spleens were lower in all treated animals than in mock-treated 108 animals; however, the differences between the three treatments were not statistically significant ( Figure 1B -109 D). In contrast, we observed significant intergroup differences in the bacterial loads at 48 hours post-infection 110
Interestingly, the bacterial load in the spleen was a strong predictor of survival ( Figure 1F ). All mock animals 119 succumbed to infection within 3 to 6 days, whereas AMX and MPLA monotherapies were associated with 120 survival rates of 13.3% and 40%, respectively. The AMX+MPLA treatment outperformed the two 121 monotherapies, with a survival rate of 86.7% -more than twice the value for MPLA, and over six times the 122 value for AMX. It is noteworthy that the difference in the survival rate between AMX+MPLA treatment and 123 high-dose AMX monotherapy (30 µg per animal; 1.2 mg/kg) was not significant (Figure S2A) . This suggests 124 that co-administration of MPLA with low-dose AMX can boost the antibiotic's efficacy to levels comparable 125 with standalone, higher-dose treatment. A similar potentiating effect was observed in the congenic BALB/c 126 mice ( Figure S2B) . Overall, the present results demonstrate that AMX+MPLA combination treatment 127 improves the therapeutic outcome of low-dose AMX and is efficacious against S. pneumoniae in vivo by 128 minimizing bacterial lung colonization and dissemination, and promoting long-term survival. 129 130
Combination treatment with AMX+MPLA mitigates pneumonia-induced lung damage 131
We next looked at whether or not MPLA-mediated pro-inflammatory signaling exacerbated inflammation due 132 to S. pneumoniae infection. To this end, the lung tissue architecture in animals having been treated 12 hours 133 post-infection with AMX, MPLA or AMX+MPLA was analyzed 48 hours post-infection. As a positive control, 134 a group of animals was treated with a single, curative, high dose of AMX (350 µg per animal; 14 mg/kg). The 135 histopathological assessment revealed that treatment with MPLA in the presence or absence of AMX did not 136 exacerbate lung inflammation (Figure 2) . Notably, all the AMX+MPLA-treated mice did not show any signs 137 of the perivascular inflammatory cell infiltration observed in the other groups (including animals having 138 receiving the curative dose of AMX). The total histopathological scores also showed that AMX+MPLA 139 treatment had the greatest impact on preservation of the lung tissue architecture, with the lowest score of 5; the 140 corresponding values were 5.75, 6.25, 8.75 and 12 in the high-dose AMX, MPLA, low-dose AMX and mock 141 groups, respectively ( Figure 2F) . These findings suggest that MPLA treatment not only mitigate the effects of 142 infection-induced tissue damage but also (when combined with AMX) promotes tissue recovery and improves 143 the antibiotic's efficacy without exacerbating inflammation. 144 7 It has already been shown that MPLA confers protection against bacterial challenge when administrated 147 prophylactically, i.e. prior to the infectious challenge (15, 17, 18) . Our study showed that MPLA also has an 148 immunomodulatory effect after the infection has been established. To further characterize the local immune 149 responses that were elicited and could participate to bacterial clearance, we used microarrays to analyze the 150 transcriptome of lung tissue. We then investigated post-treatment changes in gene expression by initially 151 comparing the AMX-and AMX+MPLA-treated groups 2, 4, and 8 h after treatment (i.e. 14, 16 and 20 h post-152 infection) (Figure 3) . The overall response to the AMX+MPLA treatment indicated an enrichment in the 153 granulocyte adhesion and diapedesis pathway and the leukocyte mobilization pathways (Figure 3B) . Moreover, 154 the difference between the AMX-and AMX+MPLA-treated groups in the number of transcripts that were 155 expressed >2-or <0.5-fold was highest at 2 h post-treatment (n=188 transcripts) and decreased over time, with 156 106 transcripts at 4 h and 13 transcripts at 8 h ( Figure 3C ). There were 173 upregulated transcripts at 2 h, 75 157 at 4 h, and 12 at 8 h ( Figure 3C) . The pattern and time course of expression in lungs suggested that the MPLA-158 induced transcriptional effects at the infection site were immediate and transient. Some of the lung transcripts 159 strongly expressed within a few hours of treatment were associated with neutrophil function (e.g. Ngp, Itgb2l, 160
and Mmp8) or encoded proteins with known antibacterial properties (e.g. CAMP or S100A8) ( Figure 3D) . 161
In a series of follow-up experiments in vivo, we confirmed the above results by using RT-qPCR assays for 162 selected genes. We extended the transcriptional study by including groups of infected and untreated animals, 163 infected and MPLA-treated animals, and uninfected and untreated (naïve) animals (Figure 4) . In line with the 164 microarray data, MPLA treatment was found to accelerate the onset of potentially antimicrobial-related Ngp, 165
Itgb2l, Mmp8, Camp, S100a9, Fkbp5, Ifitm6, Il4i1, Prok2, and Zbtb16 transcript expression in infected animals 166 in both the MPLA-only and AMX+MPLA groups (Figure 4B) . The effect of MPLA on transcript expression 167 was therefore independent of AMX treatment. The lung expression of pro-inflammatory genes coding for 168 cytokines and chemokines (such as Ccl2, Ccl20, Il1b, or Il12b) was increased by infection but was not further 169 impacted by MPLA or AMX+MPLA treatment -indicating that the expression of these genes was primarily 170 regulated in an infection-dependent manner (Figure 4B) . Given that we compared AMX+MPLA-treated with 8 we found that the transcription of some genes was somehow dependent on both infection-and MPLA-induced 175 signaling; this suggests the presence of a priming effect in which prior S. pneumoniae infection results in a more 176 robust response following the administration of MPLA. We also found that the AMX+MPLA combination did 177 not influence the neutrophil count in the lungs and spleen 12 h post-treatment ( Figure S4) . A similar pattern 178 was observed for alveolar macrophages. In contrast, the lung monocyte count was higher in the AMX+MPLA 179 group than in the mock treatment group (Figure S4A) . Overall, these results demonstrated that while a bacterial 180 pneumonia insult can prompt airway innate immune responses, the latter are enhanced by post-infection 181 treatment with MPLA; this probably contributes to greater bacterial clearance in the lungs. 182
183
The systemic response to AMX+MPLA combination treatment during pneumonia 184
Since combination treatment had significantly outperformed AMX and MPLA monotherapies by limiting 185 bacterial dissemination, we further investigated the effects of treatment on the systemic compartment. In 186 accordance with the gene expression patterns observed in the lungs, we found that the administration of MPLA 187 (whether concomitant with AMX treatment or not) resulted in the sharp release of pro-inflammatory mediators 188 (such as IL-12 p40, IL-6, and CCL2) into the blood (Figure 5) . The serum concentrations of these cytokines 189 peaked within the first two hours of administration, after which time they fell gradually and returned to baseline 190 levels within six to eight hours. It is noteworthy that during the first 12 hours post-treatment, neither mock-nor 191 AMX-treated infected animals appeared to produce this type of cytokine response -further suggesting that an 192 MPLA-dependent immediate cytokine response is instrumental in better controlling the systemic spreading of 193 bacteria. Although the MPLA-and AMX+MPLA-treated animals displayed similar blood levels of 194 inflammatory mediators, the survival rate was significantly higher in AMX+MPLA group -thus highlighting 195 the importance of the antibiotic's contribution to the therapeutic efficacy of combination treatment. Since our 196 attempts to measure MPLA in serum were not successful, we assumed that systemic as well as lung immune 197 responses were surrogate markers of MPLA's effect and thus a way to quantify the pharmacodynamics (PD). 9 AMX+MPLA treatment group were slightly but significantly different from those recorded in the AMX group. 202
Taken as a whole, these findings suggest that MPLA and AMX's particular effects and different PK profiles in 203 the systemic compartment may contribute to the observed efficacy of the combination treatment. 204
205
DISCUSSION 206
The growing incidence of AMR threatens to limit the currently available treatment options for many 207 bacterial infections. In the present study, we described an alternative strategy for combating invasive 208 pneumococcal disease in an experimental model. We used an immunomodulator (the TLR4 agonist MPLA) as 209 an add-on treatment to boost the efficacy of first-line antibiotic therapy. Our findings confirmed that the 210 outcomes of sub-curative antibiotic treatment are significantly improved (i.e. greater bacterial clearance and 211 better tissue recovery) following targeted stimulation of the host's innate immune system. 212
It has already been shown that prophylactic administration of MPLA confers protection against 213 bacterial infection in sepsis, pneumonia, and burn-wound models of disease (15, 17, 18, 22) . In our mouse 214 model of progressive pneumococcal pneumonia, we observed that the single-shot, systemic, post-infection 215 administration of MPLA was associated with a significantly lower bacterial load in lung and spleen and higher 216 survival rates. These observations demonstrated that MPLA could potentially function as a therapeutic agent. 217
On the same lines, a recent study evidenced the therapeutic effect of MPLA-containing adjuvants in the context 218 of systemic mycosis (19) . Another study reported that administration of LPS, the highly pyrogenic and toxic 219 TLR4 agonist with antibiotic is able to eliminate Salmonella invading the mesenteric lymph nodes, in contrast 220 to stand-alone antibiotic treatment (23). Together with our present findings, these literature data suggest that 221 MPLA could be repurposed as a universal antimicrobial drug whose therapeutic activity is independent of the 222 infection route and the microbial pathogen. Despite MPLA's proven adjuvant potency, a single dose of MPLA 223 alone had a limited therapeutic effect. We therefore hypothesized that MPLA's immunostimulatory properties 224 could be best exploited as a non-specific and safe booster of innate immune responses (thus improving the 225 efficacy of an otherwise suboptimal dose of antibiotic), rather than as a direct antimicrobial treatment. 226
In the present proof-of-concept study with an AMX-susceptible strain of S. pneumoniae, we sought to 227 replicate clinical conditions. Firstly, we treated the mice with a low dose of AMX; this mimics the context of 228 AMR in which a poorly administered or incorrectly dosed antibiotic treatment leads to incomplete bacterial 229 clearance or the development of resistance. Secondly, we gave the bacteria time to establish an infection prior 230 to treatment; this simulated both the lag between diagnosis and treatment, and the cascade of immune responses 231 to the initial bacterial insult. The combination of AMX and MPLA in a single administration had a greater 232 therapeutic effect than each monotherapy alone. It is known that S. pneumoniae possesses a large number of 233 virulence factors that facilitate colonization. These include cell wall peptidoglycan components and 234 pneumolysin, both of which appear to elicit MyD88-dependent immune responses via TLR2-and TLR4-235 specific pathways, respectively (24-27). Furthermore, TLR9 has been shown to have a major role in early host 236 defenses against S. pneumoniae infections (28, 29). Given that MPLA immunostimulation is biased towards 237 TRIF-mediated signaling downstream of TLR4, it is tempting to speculate that the introduction of 238 S. pneumoniae provides just the right type and right amount of primary stimulation via MyD88, which is then 239 amplified by the introduction of the secondary stimulus (MPLA) -leading to an enhanced immune response 240 through the activation of both MyD88-and TRIF-dependent pathways. Toll-like receptor-specific priming 241 induced by pneumococcal pneumonia may be a major factor in the enhanced immune response observed upon 242
MPLA treatment in our model. 243
It remains to be seen how MPLA is involved in greater bacterial clearance in the context of treatment 244 with sub-curative doses of AMX. The MPLA-associated transcriptional signature in the lungs of infected 245 animals highlighted the upregulation of genes associated with neutrophil function and tissue homing. One can 246 assume that a greater neutrophil count and an enhanced killing capacity may drive MPLA's antibacterial action 247 and synergize them with the antibiotic's effects in the airways. Our preliminary data at 12h post-treatment did 248 not highlighted changes in neutrophil number in lung and spleen; however, monocytes were found in higher 249 number in lung ( Figure S4) . Similarly, the systemic effects of MPLA-mediated signaling (such as the transient 250 production of cytokines and chemokines) may link immune cell activation to bacterial clearance in the 251 peripheral tissues. Our previous research on the TLR5 agonist flagellin identified two contributory mechanisms 252 in bacterial clearance: (i) greater infiltration of myeloid cells into the lungs and airways, and (ii) the activation 253 of IL-17/IL-22 responses by innate lymphoid cells (20, 21, 30, 31). Here, the lung transcriptional signature 254 suggests that MPLA influences the myeloid cell compartment by promoting recruitment and activating 255 antibacterial activity. In contrast to flagellin, MPLA administration was not associated with the rapid production 256 of IL-17/IL-22 by lung innate lymphoid cells; this is also the case for LPS (31). TLR signaling is associated 257 with broad range of antibacterial mechanisms in various cell types, some of which are probably independent of 12 likely to promote AMR. With a view to defining specific immune targets, it will be important to determine how 260 the MPLA-stimulated immune system cooperates with an antibiotic to improve treatment efficacy. 261
Drug PK and PD studies provide a quantitative basis for dosing regimens in humans and other animals. 262
Orally administered AMX is absorbed rapidly in humans, and has a relatively short period of serum availability 263 (32-34). The absorption in mice is reportedly even faster (35, 36). The PK characteristics of AMX indicate that 264 this antibiotic is efficacious very soon after administration. Hence, AMX's bactericidal activity depends greatly 265 on the time during which the serum concentration exceeds the minimum inhibitory concentration for its target; 266 accordingly, multiple, regular administrations are required to ensure efficacy (37, 38). Although these treatment 267 regimens are used widely, they are always associated with the risk of encouraging the development of AMR. 268
Amoxicillin's rapid PK maximum and minimum concentrations were in contrast with the PD characteristics of 269 MPLA, i.e. longer-term activation of the immune system. Our present findings suggest that the different time 270 scales of AMX's and MPLA's respective activities increased the overall efficacy of treatment when the two are 271 administered together. On a PK level, we also observed a slight increase in AMX retention when latter was 272 combined with MPLA. Future research must focus on whether and how the two substances interact specifically 273 in vivo in an infectious context. 274
Our present results highlighted on the potential of targeting innate immunity with a TLR4 agonist as a 275 viable strategy for improving antibiotic therapy against a bacterial infection. This pragmatic approach uses the 276 host's immune system to strengthen the attack against invading microorganisms, and may also help to repurpose 277 currently available drugs with known characteristics. Our experimental evidence suggests that the enhanced 278 therapeutic effect of the MPLA-AMX combination is achieved through a combination of TLR4 priming and 279 the time scales of MPLA's and AMX's respective peak biological activities. In the future, it will be important 280 System Thermo Fisher Scientific, Carlsbad, CA, USA). Specific primers used are listed in Table S1 . Relative 330 mRNA levels were determined by comparing the PCR cycle thresholds (Ct) for the gene of interest vs. Actb 331 (DCt) and then the DCt values for treated vs. untreated (mock) groups (DDCt). For the microarray analysis, total 332
RNA yield and quality were further assessed on the Agilent 2100 bioanalyzer (Agilent Technologies, Santa 333 Clara, CA, USA). One-color whole mouse (084809_D_F_20150624 slides) 60-mer oligonucleotide 8x60k v2 334 microarrays (Agilent Technologies) were used to analyze gene expression. The cRNA labelling, hybridization 335 and detection steps were carried out according to the supplier's instructions (Agilent Technologies). For each 336 microarray, cyanine-3-labeled cRNA was synthesized from 50 ng of total RNA using the low-input QuickAmp 337 labeling kit. RNA Spike-In was added to all tubes and used as a positive control in the labelling and 338 amplification steps. Next, 600 ng of each purified labelled cRNA were then hybridized and washed following have been deposited in the Gene Expression Omnibus database (accession number: GSE118860). Statistical 342 comparisons and filtering were performed with the Limma R package with 75-percentile normalization. 343
Differentially expressed genes were considered to be those with an adjusted p-value below 0.05 after the false 344 discovery rate had been checked with the Benjamini-Hochberg procedure (40). Pathways were investigated 345 using Ingenuity Pathway Analysis software (Ingenuity Systems, Redwood City, CA, USA). 
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